Videos

A professor at Polytechnique Montreal discussed advances in brain and spinal cord MRI for multiple sclerosis, including improved lesion detection, imaging standardization, and the opportunities and challenges of AI. [WATCH TIME: 5 minutes]

Decades of MG biology are now informing increasingly precise strategies that intervene at different points along the autoimmune pathway.

Effective MG care requires treatment goals that reflect not only disease activity but also each patient's priorities, responsibilities, and expectations.

The panelists discuss the safety profile of zorevunersen, highlighting the low rate of treatment discontinuations, the nature of CSF protein elevation as an asymptomatic laboratory finding, and why the safety conversation with families is fundamentally different from any discussion about standard antiseizure medications.

FcRn-targeted therapies share a therapeutic pathway but are not identical. Molecular design, dosing strategy, route of administration, and patient preference can all shape treatment selection.

FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream mechanism can provide relatively rapid control in MG.

IJMSC editors on converting a poster into a full manuscript: IMRAD structure, methods detail, clinical significance, authorship order, and AI disclosure.

A shortened diagnostic odyssey depends on recognizing red flags such as small stature and gastrointestinal symptoms, then moving promptly to exome or genome sequencing with careful, planned delivery of results.

A four-year-old with regression, ptosis, and feeding problems illustrates the textbook features of severe early-onset TK2D and the laboratory and genetic findings that confirm the diagnosis.

Neurology News Network for the week ending October 17th, 2026. [WATCH TIME: 4 minutes]

Disease severity is only part of the picture in MG, as functional demands, comorbidities, and everyday limitations can directly shape treatment urgency.

Accurate MG diagnosis begins with recognizing fluctuating, fatigable weakness and knowing when clinical or serologic findings point elsewhere.

Treatment does not end with a prescription. The panel closes by examining who owns follow-up care, and why caregivers remain the true cornerstone of managing Alzheimer's agitation over time.

When first-line therapy falls short, the decision to augment or switch is rarely straightforward. The panel examines that decision-making process alongside neurology's evolving role in managing agitation.

The panelists discuss the non-seizure outcomes from the zorevunersen studies, including incremental developmental gains on the Vineland Adaptive Behavior Scales across three years, meaningful improvements in communication, and what it means for families when their children gain functional skills that the natural history of Dravet would have predicted they would lose.

The panelists discuss the seizure efficacy data for zorevunersen, including 60 to 90% median reductions in motor seizures at the optimal dose, the absence of the honeymoon effect that commonly limits antiseizure medications in Dravet, and what sustained response over multiple years means for patients and clinicians.

Controlling MG symptoms and modifying its underlying immunology are related but distinct treatment goals. The panel explores how targeted therapies are changing the way clinicians think about remission and disease modification.

Understanding where immune dysfunction occurs in MG provides the foundation for selecting increasingly targeted therapies. The panel connects disease biology with upstream and downstream treatment strategies.

To close the series, Marisa McGinley, DO, presents her team’s model for predicting the risk of stopping MS therapy. Rebecca Cebull, CNP, and Robert Bermel, MD, explain why concrete, individualized risk data could change how patients and clinicians make treatment decisions.

The senior vice president of medical and scientific relations at the Alzheimer's Association discussed key themes in Alzheimer disease research presented at AAIC 2026. [WATCH TIME: 8 minutes]

Robert Bermel, MD, explains why progression independent of relapse activity (PIRA) is still identified only after the fact. Marisa McGinley, DO, and Rebecca Cebull, CNP, outline what clinicians can do today while targeted therapies remain on the horizon.

How clinicians can turn everyday observations into publishable research: spotting the gap, choosing the right paper type, and drafting a first manuscript.

The professor of neurology at the University of Michigan Medical School discussed the themes that defined SLEEP 2026, and what they signal for clinical practice heading into 2027. [WATCH TIME: 5 minutes]

Untreated survival ranges from about one year to two decades by onset age. Disease biology explains why muscle fails first, and early attention to swallowing and nutrition shapes outcomes.

Age at symptom onset is the strongest determinant of severity in TK2 deficiency. The panel defines the disease, its prevalence, and the presenting features that distinguish infantile, childhood, and late-onset patients.

Pharmacogenomics plays a limited role in MS care today. Marisa McGinley, DO; Rebecca Cebull, CNP; and Robert Bermel, MD, discuss why, and how multidimensional biological profiling could one day guide therapy selection.

Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker that captures progression.

Neurologists Robert Bermel, MD; Rebecca Cebull, CNP; and Marisa McGinley, DO, discuss where serum neurofilament light and GFAP fit into MS care today and why the field is still waiting on a biomarker that captures progression.

Neurology News Network for the week ending October 10th, 2026. [WATCH TIME: 5 minutes]

Cleveland Clinic's Marisa McGinley, DO; Robert Bermel, MD; and Rebecca Cebull, CNP, open the series by defining what precision medicine means in MS and how far the field has moved past a one-size-fits-all approach to treatment.